Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer: a single-arm phase 2 trial

被引：0
|
作者：
Huang, Xiang
Jin, Nan
Sun, Chunxiao
Yan, Xueqi
Yang, Fan
Liang, Yan
Li, Wei
Yin, Yongmei
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-04-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-04-04
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Inetetamab combined with pyrotinib and Chemotherapy in Pretreated Patients with HER2-positive metastatic breast cancer, a single arm, multicenter phase II clinical trial
    Zhao, Jianli
    Cai, Yangyang
    Ding, Linxiaoxiao
    Yang, Yaping
    Zou, Guorong
    Yao, Herui
    Wang, Ying
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study
    Jiang, Kuikui
    Hong, Ruoxi
    Xia, Wen
    Lu, Qianyi
    Li, Liang
    Huang, Jianhao
    Shi, Yanxia
    Yuan, Zhongyu
    Zheng, Qiufan
    An, Xin
    Xue, Cong
    Huang, Jiajia
    Bi, Xiwen
    Chen, Meiting
    Zhang, Jingmin
    Xu, Fei
    Wang, Shusen
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 513 - 521
  • [3] Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial
    Jin, Nan
    Xu, Yi
    Wang, Siqi
    Sun, Chunxiao
    Yan, Xueqi
    Yang, Fan
    Liang, Yan
    Chen, Weiwei
    Huang, Xiang
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (01): : 31 - 37
  • [4] A Multicenter, Retrospective, Real World Study of Inetetamab Combined with Pyrotinib and Vinorelbine as Treatment for HER2-positive Metastatic Breast Cancer
    Yin, Yongmei
    Li, Wei
    Huang, Xiang
    Jin, Nan
    Wu, Xinyu
    Sun, Chunxiao
    Hua, Yijia
    CANCER RESEARCH, 2024, 84 (09)
  • [5] Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial
    Zhao, Jianli
    Yu, Yunfang
    Ren, Wei
    Ding, Linxiaoxiao
    Chen, Yongjian
    Yuan, Peng
    Yue, Jian
    Yang, Yaping
    Zou, Guorong
    Chen, Tao
    Chai, Jie
    Zhang, Li
    Wu, Wenjing
    Zeng, Yinduo
    Gui, Xiujuan
    Cai, Yangyang
    Luo, Simin
    Yuan, Zhongyu
    Zhang, Kang
    Yao, Herui
    Wang, Ying
    MEDCOMM, 2025, 6 (01):
  • [6] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Min Yan
    Limin Niu
    Huimin Lv
    Mengwei Zhang
    Jing Wang
    Zhenzhen Liu
    Xiuchun Chen
    Zhenduo Lu
    Chongjian Zhang
    Huiai Zeng
    Shengnan Zhao
    Yajing Feng
    Huihui Sun
    Huajun Li
    Nature Communications, 14
  • [7] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Yan, Min
    Niu, Limin
    Lv, Huimin
    Zhang, Mengwei
    Wang, Jing
    Liu, Zhenzhen
    Chen, Xiuchun
    Lu, Zhenduo
    Zhang, Chongjian
    Zeng, Huiai
    Zhao, Shengnan
    Feng, Yajing
    Sun, Huihui
    Li, Huajun
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [8] A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
    Jin, N.
    Yin, Y.
    Li, W.
    Huang, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1492 - S1492
  • [9] Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study
    Liu, Jiaxuan
    He, Maiyue
    Jiang, Mingxia
    Zhou, Shihan
    Zhang, Mengqi
    Li, Yiqun
    Chen, Shanshan
    Cai, Ruigang
    Mo, Hongnan
    Lan, Bo
    Ma, Fei
    Xu, Binghe
    Li, Qiao
    BMC CANCER, 2024, 24 (01)
  • [10] Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
    Li, Yi
    Qiu, Yixuan
    Li, Huihui
    Luo, Ting
    Li, Wei
    Wang, Hong
    Shao, Bin
    Wang, Biyun
    Ge, Rui
    FRONTIERS IN ONCOLOGY, 2021, 11
12345